Compare Abeona Therapeutics Inc (ABEO) vs CubeSmart (CUBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs CubeSmart — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while CubeSmart trades at $40 (market cap $9.26B). The key difference: CubeSmart is far larger — about 24.8× Abeona Therapeutics Inc's market cap, and CubeSmart pays a 5.19% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CUBE | |
|---|---|---|
Market Cap | $373.32M | $9.26B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $42.60 |
52-Week Low | $4.17 | $35.36 |
Enterprise Value | $228.22M | $12.75B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CubeSmart (CUBE) trades at $40.88, down 0.24% on the day, with a neutral technical signal and mixed earnings history. The company reported Q1 2026 EPS of $0.63, beating expectations, and maintains strong profitability with a 28.93% net income margin. Recent news highlights the upcoming Q2 2026 earnings release on July 30, 2026, and a declared dividend of $0.53 per share.
Outlook is balanced with a consensus price target of $43.17 suggesting modest upside, but risks include a high debt load and interest rate sensitivity. The stock offers a solid dividend yield, yet faces headwinds from macroeconomic uncertainty and competitive pressures in the REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
